Get the Stockscreener App
8.03
0.37%
0.03
After Hours:
8.03
Gh Research Plc stock is traded at $8.03, with a volume of 31,118.
It is up +0.37% in the last 24 hours and up +23.73% over the past month.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.
See More
Previous Close:
$8.00
Open:
$8.1
24h Volume:
31,118
Relative Volume:
0.70
Market Cap:
$417.79M
Revenue:
-
Net Income/Loss:
$-32.32M
P/E Ratio:
-11.69
EPS:
-0.687
Net Cash Flow:
$-36.14M
1W Performance:
-0.86%
1M Performance:
+23.73%
6M Performance:
-31.25%
1Y Performance:
-2.78%
1-Day Range:
$7.7342
$8.305
1-Week Range:
$7.7342
$9.02
52-Week Range:
$5.05
$14.99
Gh Research Plc Stock (GHRS) Company Profile
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-16-22 | Initiated | H.C. Wainwright | Buy |
| Jun-16-22 | Initiated | ROTH Capital | Buy |
Gh Research Plc Stock (GHRS) Latest News
GH Research (NASDAQ:GHRS) Stock Price Up 0.6%Time to Buy? - MarketBeat
GH Research (NASDAQ:GHRS) Shares Up 0.7%Still a Buy? - MarketBeat
abrdn plc Raises Stock Holdings in Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
(GHRS) On The My Stocks Page - Stock Traders Daily
GH Research (NASDAQ:GHRS) Shares Up 2.2%Time to Buy? - MarketBeat
Standard Chartered Bank Ghana PLC (SCB.gh) Q32024 Interim Report - AfricanFinancials
GH Research PLC (NASDAQ:GHRS) Sees Significant Growth in Short Interest - MarketBeat
GH Research (NASDAQ:GHRS) Shares Down 1%What's Next? - MarketBeat
GH Research (NASDAQ:GHRS) Shares Up 2.8%Here's What Happened - MarketBeat
GH Research (NASDAQ:GHRS) Trading Down 0.1%Here's Why - MarketBeat
Acromegaly Market Innovations Investigated by Size, Share, Trends And Outlook Report 2024-2033 - WhaTech
Psychedelic Drugs Industry Size, Growth Opportunities - openPR
GH Research (NASDAQ:GHRS) Trading 3.3% HigherHere's Why - MarketBeat
How To Trade (GHRS) - Stock Traders Daily
Stanbic Bank facilitates GH¢200m bond issuance for Kasapreko PLC - Graphic Online
GGBL announces dividend of GH¢0.022 per share for shareholders - Myjoyonline
Objective long/short (GHRS) Report - Stock Traders Daily
Tullow Oil Plc (TLW.gh) HY2024 Presentation - AfricanFinancials
When (GHRS) Moves Investors should Listen - Stock Traders Daily
Mackenzie Financial Corp Has $148.34 Million Holdings in Ferguson plc (NASDAQ:FERG) - Defense World
GH Research PLC (NASDAQ:GHRS) Shares Bought by Lynx1 Capital Management LP - Defense World
Lynx1 Capital Management LP Has $46.25 Million Holdings in GH Research PLC (NASDAQ:GHRS) - MarketBeat
Hsbc Holdings PLC Has $2.01 Million Stake in Guardant Health, Inc. (NASDAQ:GH) - Defense World
ACTH and GH Function Tests Market – Industry Forecast and Growth Potential - Elektrotransports.lv
Magic mushroom market set to go gangbusters, Irish researcher says - Mugglehead
(GHRS) Investment Report - Stock Traders Daily
Guardant Health (NASDAQ:GH) Shares Down 3.5% - Defense World
Guardant Health, Inc. (GH) Stock Price, News, Quote & History - Yahoo Finance
GH Research Engages Investors at Healthcare Conference - TipRanks
GH Research to Engage at Global Investment Conference - TipRanks
GH Research PLC (NASDAQ:GHRS) to Post FY2024 Earnings of ($0.75) Per Share, HC Wainwright Forecasts - Defense World
GH Research (GHRS) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Market Exclusive
HC Wainwright Weighs in on GH Research PLC's FY2024 Earnings (NASDAQ:GHRS) - MarketBeat
Irish Biotech Firm GH Research Sees Cash Decline in Q2, Advances Psychedelic Drug Trials - MSN
GH Research (NASDAQ:GHRS) Receives Buy Rating from HC Wainwright - Defense World
GH Research (NASDAQ:GHRS) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
GH Research (NASDAQ:GHRS) Receives Market Outperform Rating from JMP Securities - Defense World
GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates - Yahoo Finance UK
JMP Securities Reaffirms Market Outperform Rating for GH Research (NASDAQ:GHRS) - MarketBeat
GH Research (NASDAQ:GHRS) Issues Quarterly Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Trend Tracker for (GHRS) - Stock Traders Daily
GH Research names new CEO amid clinical trials - Investing.com India
GH Research to Connect at Global Healthcare Conference - TipRanks
GH Research (NASDAQ:GHRS) Shares Gap Down to $10.50 - MarketBeat
GH Research names new CEO amid clinical trials By Investing.com - Investing.com Canada
GH Research’s losses persist as it tries to lift FDA hold for GH001 - Green Market Report
GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer - Yahoo Finance UK
GH Research Appoints New CEO, Advances Trials - TipRanks
GH Research appoints Velichka Valcheva to CEO - TipRanks
Gemini Therapeutics (NASDAQ:GMTX) versus GH Research (NASDAQ:GHRS) Head-To-Head Review - Defense World
Gh Research Plc Stock (GHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):